Nijhawan Pardeep 4

What Happened
Pardeep Nijhawan, CEO of Edesa Biotech, was granted 2,578 restricted share units (RSUs) that vested in full upon grant under the Issuer's 2019 Equity Incentive Compensation Plan. The acquisition is reported at $0.00 per share on the Form 4 (transaction code A — Award/Grant).

Key Details

• Transaction date: 2026-04-01 (grant that vested in full upon grant)
• Reported acquisition: 2,578 shares; reported price $0.00 per share
• Filing date: Form 4 filed 2026-04-10 (appears late relative to the April 1 transaction)
• Shares owned after transaction: not specified in the provided filing
• Footnotes: F1 confirms RSUs vested in full upon grant under the 2019 Equity Incentive Compensation Plan. F2 and F3 note entities wholly owned by the reporting person and a co-trustee status; the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.

Context
This was a compensation award (RSUs that vested on grant), not an open-market purchase or sale. Such grants reflect compensation/long-term incentives rather than an immediate trading decision and should not be interpreted by themselves as a bullish or bearish signal.